Aushon announced its plans today for an upcoming global launch of its new multiplex protein biomarker platform, which incorporates several engineering breakthroughs to deliver ELISA-level performance. Aushon's ultra-precise microarray printing, novel assay design, astronomy-grade imaging and advanced analytics provide the sensitivity and reproducibility of single-plexed ELISA in a multiplexed format. The technology is designed to meet the needs of scientists who have been unable to find a multiplexing solution that consistently delivers the required performance in their studies.
"Based on feedback gathered over the past several years, scientists in general have been dissatisfied with the performance of earlier generation multiplex systems," said Pete Honkanen, Founder and CEO of Aushon. "They love the idea of what multiplexing can deliver in terms of overall lab productivity, reduced sample consumption and lower cost per study but are seeing relatively poor performance vis-a-vis traditional ELISA...which has constrained the growth in the use of these platforms in the protein biomarker market. We're confident that we've addressed that issue."
Aushon has already placed systems with several early adoptors at Big Pharma and leading academic institutions including Duke University Medical Center. "The initial results demonstrated from Aushon's new system were very encouraging," said Dr. Andrew Nixon, Co-Director of the Phase I Biomarker Laboratory at Duke. "The sensitivity and consistency were equivalent to or better than the singleplex ELISA results for the markers evaluated."
Aushon plans a full global launch in June. The platform will be sold through Aushon's direct sales team in North America and Europe. In addition, Fisher Scientific is now distributing Aushon's immunoassay products and services in North America, primarily targeting the academic segment.
Researchers uncover mechanism behind mitochondrial dysfunction in Alzheimer's